Medical/Pharmaceuticals
Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended June 30,...
2026-08-11 17:45
2648
Haleon and Singapore's Agency for Science, Technology and Research (A*STAR) Launch New Clinical Study on Women's Metabolic Health in Asia
* A new clinical study on the multivitamin and mineral supplement Centrum is designed to generate evidence on metabolic health in midlife Asian women - a group often underrepresented in global nutrition research. * The study will contribute to a better understanding of preventive healthcare a...
2026-08-11 11:41
2574
Global Study Results Published in Aesthetic Surgery Journal Open Forum Show Link Between Self-Confidence and Aesthetics
Publication in the peer-reviewed journal reinforces the study's insights and validates what clinicians frequently observe – that the impact of aesthetic treatments extends beyond physical appearance. * The Pillars of Confidence Global Study, supported by Merz Aesthetics, evaluated the impact ...
2026-08-11 10:00
2072
Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery
LAGUNA HILLS, Calif. and SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and a prominent strategic investor led a subsequent tranche, with participation f...
2026-08-11 09:30
3612
Lifespan Vision Ventures Leads Remedium Bio's Series A Financing
Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financi...
2026-08-10 22:00
2776
Unveiling a Smarter Future for Dentistry at China Dental Show 2026
AI-powered clinical solutions, hands-on experiences and global business opportunities will come together in Shanghai from October 13 to 16 SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- China Dental Show 2026 (CDS 2026) will take place from October 13 to 16 at the National Exhibition and Convention Cen...
2026-08-10 21:00
3217
NYSE Content Update: Goldman Sachs Asset Management Launches Two New ETFs
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 10, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...
2026-08-10 20:56
5934
POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine
GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a clos...
2026-08-10 20:00
3898
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly...
2026-08-10 19:00
4716
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10...
2026-08-10 17:36
3242
/C O R R E C T I O N -- United Imaging/
In the news release, Chinese and Indonesian cardiologists complete Southeast Asia's first "noise-free" cardiac procedure in Jakarta, issued 09-Aug-2026 by United Imaging over PR Newswire, the 2nd paragraph, 1st sentence, should read "The procedure, performed recently" rather than "The procedure, ...
2026-08-10 16:45
4695
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), i...
2026-08-10 12:05
2709
2026 Global Health Summit Opens in Hong Kong -- Global Healthcare Leaders Convene: Bringing Breakthroughs to Patients
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- The 2026 Global Health Summit ("GHS 2026"), jointly hosted by New Frontier Group ("New Frontier") and the Hong Kong Investment Corporation Limited ("HKIC"), opened today at the Hong Kong Convention and Exhibition Centre for a two-day programme. Held under ...
2026-08-10 11:00
800
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
SHANGHAI, Aug. 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site inspect...
2026-08-10 08:00
2628
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX e...
2026-08-08 15:46
4469
Alebund's AP301 NDA Accepted for Review by China's NMPA
SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatmen...
2026-08-07 18:40
3378
Check out Hainan's Pioneering Medical Hub
Uncover the New Charms of Boao Lecheng Medical Tourism HAIKOU, China, Aug. 7, 2026 /PRNewswire/ -- A news report from PDDC: Coastal scenery soothes body and mind, while cutting‑edge medical services empower health‑and‑wellness tourism. Bolstered by the opening‑up dividends of Hainan Free Trade P...
2026-08-07 18:27
2926
Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China
NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ -- TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026,...
2026-08-07 14:44
4075
CLASSYS Appoints Former Samsung Electronics and Vuno Executive Dr. Taek-Soo Kim as Chief Technology Officer, Accelerating Its Evolution into a Global Medical Aesthetics Technology Company
SEOUL, South Korea, Aug. 7, 2026 /PRNewswire/ -- CLASSYS (KOSDAQ: 214150), a global medical aesthetics platform company, announced the appointment of Dr. Taek-Soo Kim, a distinguished technology management expert, as its new Chief Technology Officer (CTO) and Head of Research and Development. ...
2026-08-07 08:16
5104
Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its Phase II clinical trial evaluating RAG-17, an ...
2026-08-06 19:30
2418
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 280 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
19342
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
12324
MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market
2026-09-26 08:55
9598
